Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Shaky science at FDA

WASHINGTON - The FDA does not have sufficient resources and is not currently organized to cope with the accelerating pace of technical innovation and scientific challenges it is likely to meet in the near future, senior agency officials, and academic experts agree. The agency has begun a wide-ranging review and reorganization of its scientific activities that is intended to ensure that it is able to cope with the variety of new technologies and scientific discoveries that its reviewers and regulators will face.

At the same time, the agency is being forced to cut back the scientific research capabilities of the Center for Biologics Evaluation and Research (CBER). The FDA is warning that it will be forced to reassign almost 100 CBER researchers to desk jobs over the

Read the full 1265 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE